TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i> -Mutant Tumors to Anti–PD-1 Immunotherapy
Targeting CoREST with TNG260 sensitizes STK11-deficient non-small cell lung cancer to anti-PD-1 immunotherapy, offering a potential treatment for patients not served by existing therapies. See related commentary by Lin and Shen, p. 3821.
Authors
- Brian Doyon
- Suleman S. Hussain (ORCID: https://orcid.org/0000-0003-1342-143X)
- Jiehui Deng (ORCID: https://orcid.org/0000-0001-7986-8643)
- Preksha Shahagadkar
- Alfonso Lopez (ORCID: https://orcid.org/0009-0007-2479-8538)
- David R. Spigel (ORCID: https://orcid.org/0000-0003-3215-9465)
- Hsin‐Jung Wu (ORCID: https://orcid.org/0009-0005-3474-6171)
- Kwok‐Kin Wong (ORCID: https://orcid.org/0000-0001-6323-235X)
- Minjie Zhang (ORCID: https://orcid.org/0000-0003-1778-3761)
- Hideo Watanabe (ORCID: https://orcid.org/0000-0002-6017-6361)
- Kenjie Amemiya
- John P. Maxwell (ORCID: https://orcid.org/0000-0002-5969-6490)
- Magdalena A. Ploszaj (ORCID: https://orcid.org/0009-0004-8860-3662)
- Judy S. Wang (ORCID: https://orcid.org/0000-0003-4789-4913)
- Ayushi S. Patel (ORCID: https://orcid.org/0000-0002-4959-5397)
- Chengyin Min
- Adam Crystal (ORCID: https://orcid.org/0000-0002-2302-2654)
- Mary Meynardie (ORCID: https://orcid.org/0000-0002-8791-9137)
- Jonathan Wade Goldman (ORCID: https://orcid.org/0000-0002-4925-8243)
- Michela Ranieri (ORCID: https://orcid.org/0000-0002-3833-3594)
- Heather DiBenedetto (ORCID: https://orcid.org/0009-0005-0211-8154)
- Iga Sienczylo
- Jannik N. Andersen (ORCID: https://orcid.org/0000-0003-4528-2120)
- Douglas A. Whittington (ORCID: https://orcid.org/0000-0002-5946-8543)
- Reshmee Bhattacharya (ORCID: https://orcid.org/0000-0003-4333-0395)
- Alan Huang (ORCID: https://orcid.org/0000-0001-5501-0212)
- Yi Yu (ORCID: https://orcid.org/0000-0002-2223-337X)
- Alexander I. Spira (ORCID: https://orcid.org/0000-0003-1303-0447)
- Ferdinandos Skoulidis (ORCID: https://orcid.org/0000-0002-4676-4503)
- Soumyadip Sahu (ORCID: https://orcid.org/0000-0002-2497-864X)
- Janaye Stephens
- Leanne G. Ahronian (ORCID: https://orcid.org/0000-0001-7233-5879)
- Alice Tsai
- Patrick McCarren (ORCID: https://orcid.org/0000-0003-2084-6655)
- David J. Guerin
- Andre Mignault
- Julie A. Shields (ORCID: https://orcid.org/0000-0002-0725-5888)
- Lauren R. Flynn
- Salman Rafi Punekar (ORCID: https://orcid.org/0000-0002-7613-6305)
- Gerald S. Falchook (ORCID: https://orcid.org/0000-0001-9165-2191)
- Yeuan Ting Lee (ORCID: https://orcid.org/0000-0001-9356-5681)
- Nikitha M. Das (ORCID: https://orcid.org/0000-0002-7482-3371)
- Yi Jer Tan (ORCID: https://orcid.org/0000-0003-2145-2105)
- Jaylen M. Powell (ORCID: https://orcid.org/0009-0005-0721-1788)
- Ke Geng (ORCID: https://orcid.org/0000-0002-6080-3740)
- Samuel R. Meier (ORCID: https://orcid.org/0000-0002-7026-2722)
- Jacques Ermolieff
- Ting Chen (ORCID: https://orcid.org/0000-0003-1725-7956)
- Brian J. McMillan (ORCID: https://orcid.org/0000-0002-3134-7774)
- Xinyuan Wu
- Brian B. Haines
- Laney Danielczyk
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- UCLA Health (US)
- NYU Langone Health (US)
- Tango Therapeutics (United States) (US)
- Hinge Health (US)
- Sarah Cannon (US)
- Jnana Therapeutics (United States) (US)
- Florida Cancer Specialists & Research Institute (US)
- HealthONE (US)
- Virginia Cancer Specialists (US)
- Tennessee Oncology (US)
- The US Oncology Network (US)
- Io Therapeutics (United States) (US)
- New York University (US)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1158/0008-5472.can-25-0998
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Celgene
- NYU Langone Medical Center
- National Institutes of Health
- Genentech
- Foundation Medicine
- National Cancer Institute
- Janssen Pharmaceuticals